---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-248059"
form_type: "8-K"
ticker: "VTRS"
cik: "0001792044"
company_name: "Viatris Inc"
filed_at: "2023-10-02T23:59:59+00:00"
generated_at: "2026-06-10T06:27:40.531007+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Viatris announces $6.94B in gross proceeds from remaining divestitures, achieving >12x multiple

## Summary
- Aggregated gross proceeds up to $6.94B from biosimilars, OTC, API, Women's Health, and non-core markets.
- OTC offer: gross consideration up to ~$2.17B (12.8x multiple); API/Women's Healthcare: up to ~$1.2B (9.9x).
- Strategic decision to retain Viagra, Dymista, select OTC in certain markets; retained value ~$1.6B.
- Divestitures expected to close by end of H1 2024; net proceeds to be used for debt paydown targeting 3.0x gross leverage.
- Up to 12 facilities and >6,000 employees (15% workforce) may be conveyed, simplifying organization.

## SEC filing metadata
- accession: 0001193125-23-248059
- form_type: 8-K
- ticker: VTRS
- cik: 0001792044
- company_name: Viatris Inc
- filed_at: 2023-10-02T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1792044/000119312523248059/0001193125-23-248059-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1792044/000119312523248059/d470078d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-248059
- JSON: https://secwatch.observer/filing/0001193125-23-248059.json
- Plain text: https://secwatch.observer/filing/0001193125-23-248059.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.